Literature DB >> 25238641

Herpes simplex virus 2 ICP34.5 confers neurovirulence by regulating the type I interferon response.

Katie L Davis1, Maria Korom1, Lynda A Morrison2.   

Abstract

The γ34.5 gene of herpes simplex virus (HSV) 2 encodes ICP34.5, which enhances HSV-2 neurovirulence by an unknown mechanism. We found that an HSV-2 γ34.5-null mutant (γ34.5(-/-)) replicated less robustly than its rescue virus (γ34.5R) in wild-type mouse embryo fibroblasts (MEFs), and in cells primed with IFNβ. Increased eIF2α phosphorylation correlated with γ34.5(-/-) attenuation. However, γ34.5(-/-) achieved titers equivalent to γ34.5R in MEFs lacking the type I IFN receptor (IFNα/βR(-/-)) or lacking protein kinase R. γ34.5(-/-) also replicated poorly in the vaginal mucosa of wild-type mice, caused little genital inflammation, and spread to the nervous system at lower levels compared to γ34.5R. In IFNα/βR(-/-) mice, however, γ34.5(-/-) regained the capacity to replicate and cause disease equivalent to γ34.5R after intravaginal infection or direct inoculation into the central nervous system. Thus, the capacity of HSV-2 ICP34.5 to interdict the type I IFN response in vivo largely determines its neurovirulence.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CNS; Central nervous system; HSV-2; Herpes simplex virus; IFN; Interferon; Vaginal

Mesh:

Substances:

Year:  2014        PMID: 25238641     DOI: 10.1016/j.virol.2014.08.015

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.

Authors:  Hiroshi Nakashima; Tran Nguyen; Kazue Kasai; Carmela Passaro; Hirotaka Ito; William F Goins; Imran Shaikh; Ronald Erdelyi; Reiko Nishihara; Ichiro Nakano; David A Reardon; Ana C Anderson; Vijay Kuchroo; E Antonio Chiocca
Journal:  Clin Cancer Res       Date:  2018-03-06       Impact factor: 12.531

2.  Herpes simplex virus ICP27 regulates alternative pre-mRNA polyadenylation and splicing in a sequence-dependent manner.

Authors:  Shuang Tang; Amita Patel; Philip R Krause
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-10       Impact factor: 11.205

3.  Herpes Simplex Virus 1 γ134.5 Protein Inhibits STING Activation That Restricts Viral Replication.

Authors:  Shuang Pan; Xing Liu; Yijie Ma; Youjia Cao; Bin He
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

4.  Herpes Simplex Virus 1 ICP34.5 Alters Mitochondrial Dynamics in Neurons.

Authors:  Richard Manivanh; Jesse Mehrbach; Audra J Charron; Andrew Grassetti; Stacey Cerón; Sean A Taylor; Jorge Rubén Cabrera; Scott Gerber; David A Leib
Journal:  J Virol       Date:  2020-07-01       Impact factor: 5.103

Review 5.  Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes.

Authors:  Marlana Orloff
Journal:  Oncolytic Virother       Date:  2016-10-04

6.  The Herpes Simplex Virus Neurovirulence Factor γ34.5: Revealing Virus-Host Interactions.

Authors:  Douglas R Wilcox; Richard Longnecker
Journal:  PLoS Pathog       Date:  2016-03-10       Impact factor: 6.823

7.  A novel oncolytic herpes simplex virus armed with the carboxyl-terminus of murine MyD116 has enhanced anti-tumour efficacy against human breast cancer cells.

Authors:  Lin Cheng; Hua Jiang; Jingjing Fan; Jiani Wang; Pan Hu; Ying Ruan; Renbin Liu
Journal:  Oncol Lett       Date:  2018-03-13       Impact factor: 2.967

8.  The Mutation of the Genes Related to Neurovirulence in HSV-2 Produces an Attenuated Phenotype in Mice.

Authors:  Lei Liu; Jishuai Cheng; Tangwei Mou; Ying Zhang; Xingli Xu; Jingjing Zhang; Xueqi Li; Xiao Feng; Xiangxiong Xu; Yun Liao; Shengtao Fan; Lichun Wang; Guorun Jiang; Qihan Li
Journal:  Viruses       Date:  2020-07-17       Impact factor: 5.048

Review 9.  Resources to Discover and Use Short Linear Motifs in Viral Proteins.

Authors:  Peter Hraber; Paul E O'Maille; Andrew Silberfarb; Katie Davis-Anderson; Nicholas Generous; Benjamin H McMahon; Jeanne M Fair
Journal:  Trends Biotechnol       Date:  2019-08-16       Impact factor: 19.536

Review 10.  Oncolytic viruses: a new class of immunotherapy drugs.

Authors:  Howard L Kaufman; Frederick J Kohlhapp; Andrew Zloza
Journal:  Nat Rev Drug Discov       Date:  2015-09       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.